183 Folgen

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Internal Medicine Video PeerVoice

    • Wissenschaft

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?

    Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?

    Go online to peervoice.com/AVH860 to view the entire programme with slides. After completing “Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?”, participants will be able to: Distinguish different types of patients with severe asthma who may benefit from biologic therapies; and Propose management strategies for these patients based on current clinical data.

    • 24 Min.
    • video
    Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies

    Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies

    Go online to peervoice.com/EQD860 to view the entire programme with slides. After completing “Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies”, participants will be able to: Evaluate recent clinical data for current first-line treatment options in patients with advanced EGFR-mutant NSCLC, within the context of long-term care; Discuss strategies and options for managing specific challenges that can impact first-line treatment selection in patients with advanced EGFR-mutant NSCLC; and Formulate optimal treatment strategies that maximise outcomes in patients with advanced EGFR-mutant NSCLC.

    • 26 Min.
    • video
    A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice

    A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice

    Go online to peervoice.com/QRD860 to view the entire programme with slides. After completing “A Case in Point: Navigating the Differential Diagnosis of aHUS in Clinical Practice”, participants will be able to: Outline the differential diagnosis of a patient with atypical hemolytic uremic syndrome (aHUS); Discuss how to identify patients with aHUS; and Overview currently available therapies to manage aHUS.

    • 7 Min.
    • video
    Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike

    Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike

    Go online to peervoice.com/VGT860 to view the entire programme with slides. After completing “Breaking the Cycle of Severe Hypoglycemia in Diabetes: Educating Clinicians and Patients Alike”, participants will be able to: Identify patients at risk of severe hypoglycemia; Evaluate the benefits and limitations of current pharmacologic strategies for the management of severe hypoglycemia; and Formulate approaches for educating patients and their caregivers about severe hypoglycemia and early and appropriate treatment.

    • 20 Min.
    • video
    Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data

    Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data

    Go online to peervoice.com/TWQ860 to view the entire programme with slides. After completing “Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data”, participants will be able to: Explain the rationale for targeted therapy in early-stage EGFR-mutant NSCLC; Assess recent clinical data for EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy for patients with early-stage EGFR-mutant NSCLC; and Describe how EGFR TKIs may impact the treatment paradigm for early-stage EGFR-mutant NSCLC.

    • 18 Min.
    • video
    Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?

    Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?

    Go online to peervoice.com/CPA860 to view the entire programme with slides. After completing “Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?”, participants will be able to: Evaluate recent survival data associated with androgen receptor (AR)-targeted therapies in patients with nmCRPC; Discuss why quality of life (QoL) should be prioritised when managing patients with nmCRPC; and Propose treatment plans for patients with nmCRPC that optimally balance efficacy with QoL, with a focus on adverse events.

    • 1 Std. 31 Min.

Top‑Podcasts in Wissenschaft

Zuhörer haben auch Folgendes abonniert:

Mehr von PeerVoice